Dare Bioscience (DARE) & Its Rivals Financial Analysis

Dare Bioscience (NASDAQ:DARE) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its peers? We will compare Dare Bioscience to related companies based on the strength of its institutional ownership, analyst recommendations, valuation, risk, earnings, profitability and dividends.

Insider and Institutional Ownership

6.7% of Dare Bioscience shares are held by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 3.4% of Dare Bioscience shares are held by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Dare Bioscience has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500. Comparatively, Dare Bioscience’s peers have a beta of -3.71, meaning that their average stock price is 471% less volatile than the S&P 500.

Earnings and Valuation

This table compares Dare Bioscience and its peers top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Dare Bioscience	$1.37 million	-$13.40 million	-0.91
Dare Bioscience Competitors	$3.56 billion	$3.19 billion	555.10

Dare Bioscience’s peers have higher revenue and earnings than Dare Bioscience. Dare Bioscience is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Dare Bioscience and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dare Bioscience	-803.80%	-748.30%	-38.75%
Dare Bioscience Competitors	-2,380.38%	-217.94%	-15.54%

Analyst Ratings

This is a breakdown of recent recommendations for Dare Bioscience and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dare Bioscience	1	0	3	0	2.50
Dare Bioscience Competitors	7798	13888	25778	1037	2.41

Dare Bioscience currently has a consensus target price of $5.00, indicating a potential upside of 682.47%. As a group, “Pharmaceuticals” companies have a potential upside of 25.63%. Given Dare Bioscience’s stronger consensus rating and higher probable upside, research analysts plainly believe Dare Bioscience is more favorable than its peers.

Summary

Dare Bioscience peers beat Dare Bioscience on 8 of the 13 factors compared.

About Dare Bioscience

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.